WellDoc raises $20 million for mobile diabetes prescription therapy

Baltimore-based healthcare technology company WellDoc has secured $20 million in financing from Merck Global Health Innovation Fund and Windham Venture Partners for the marketing and rollout of BlueStar, the prescription version of the company's DiabetesManager, which runs on smartphones and tablets.

"This investment will help WellDoc launch and commercialize BlueStar, the world's first mobile prescription therapy for type 2 diabetes, on a nationwide basis," said Ryan Sysko, co-founder and CEO of WellDoc, in a written statement.

Launched in June, BlueStar is the first FDA-cleared mobile prescription therapy for type 2 diabetes with insurance reimbursement, which requires a prescription from a licensed healthcare provider and is "reimbursed and adjudicated" as a pharmacy benefit similar to other prescription products. Announcement

 

Suggested Articles

The newly launched Center for Connected Health will be largest telehealth hub in the Philadelphia region, according to Penn Medicine.

The FDA commissioner wants to use additional funding under Trump's budget to advance digital health initiatives and integrate real-world data.

The FDA's approval of an app that uses AI to notify specialists of a potential stroke offers new possibilities for triage software that uses CDS.